Pentostatin, Chlorambucil and Prednisone Therapy for B-Chronic Lymphocytic Leukemia: A Phase I/II Study by the Eastern Cooperative Oncology Group Study E1488

References

• Hansen, M.M. (1973) "Chronic lymphocytic leukaemia. Clinical studies based on 189 cases followed for a long time", Scandinavian Journal of Haematology— Supplement urn, 18, 3–286.
   Google Scholar
• Rai, KR., Sawitsky, A., Cronkite, E.P., Chanana, A.D., Levy, R.N. and Pasternack, B.S. (1975) "Clinical staging of chronic lympho-cytic leukemia", Blood, 46(2), 219–234.
   PubMed Web of Science ®Google Scholar
• Binet, J.L., Catovsky, D. and Chandra, P. (1981) "Chronic lymphocytic leukemia: Proposals for a revised prognostic staging system", British Journal of Haematology, 48, 365–367.
   Google Scholar
• Raphael, B., Andersen, J.W., Silber, R., et al. (1991) "Comparison of chlorambucil and prednisone versus cyclophosphamide, vincris-tine, and prednisone as initial treatment for chronic lymphocytic leukemia: long-term follow-up of an Eastern Cooperative Oncology Group randomized clinical trial", Journal of Clinical Oncology, 9(5), 770— 776.
   PubMed Web of Science ®Google Scholar
• Han, T., Ezdinli, E.Z., Shimaoka, K. and Desai, D.V. (1973) "Chlorambucil vs. combined chlorambucil-corticosteroid therapy in chronic lymphocytic leukemia", Cancer, 31(3), 502— 508.
   Google Scholar
• Keller, J.W., Knospe, W.H., Raney, M., et al. (1986) "Treatment of chronic lymphocytic leukemia using chlorambucil and prednisone with or without cycle-active consolidation chemotherapy. A South-eastern Cancer Study Group Trial", Cancer, 58(6), 1185–1192.
   Google Scholar
• Hansen, M.M., Andersen, E. and Birgens, H. (1991) "CHOP versus chlorambucil + prednisolone in chronic lymphocytic leukemia", Leukemia Lymphoma, 5(suppl), 97 — 100.
   Google Scholar
• Dighiero, G., Maloum, K., Desablens, B., et al. (1998) "Chlor-ambucil in indolent chronic lymphocytic leukemia. French Co-operative Group on Chronic Lymphocytic Leukemia", New England Journal of Medicine, 338(21), 1506 — 1514.
   PubMed Web of Science ®Google Scholar
• Keating, M.J. (1990) "Fludarabine phosphate in the treatment of chronic lymphocytic leukemia", Seminars in Oncology, 17(5 Suppl 8), 49 — 62.
   PubMed Web of Science ®Google Scholar
• Keating, M.J., Kantarjian, H., O'Brien, S., et al. (1991) "Fludar-abine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia", Journal of Clinical Oncology, 9(1), 44–49.
   PubMed Web of Science ®Google Scholar
• Rai, KR., Peterson, B. and Elias, L. (1996) "A randomized comparison of fludarabine and chlorambucil for patients with previously untreated chronic lymphocytic leukemia. A CALGB, SWOG, CTG/NCI-C and ECOG intergroup study", Blood, 88, 141a.
   Google Scholar
• Greyer, MR., Leiby, J.M., Kraut, E.H., et al. (1985) "Low-dose deoxycoformycin in lymphoid malignancy", Journal of Clinical Oncology, 3(9), 1196— 1201.
   PubMed Web of Science ®Google Scholar
• Dillman, R.O., Mick, R. and McIntyre, O.R. (1989) "Pentostatin in chronic lymphocytic leukemia: a phase II trial of Cancer and Leukemia group B", Journal of Clinical Oncology, 7(4), 433–438.
   PubMed Web of Science ®Google Scholar
• Dearden, C. and Catovsky, D. (1990) "Deoxycoformycin in the treatment of mature B-cell malignancies", British Journal of Cancer, 62(1), 4 — 5.
   PubMed Web of Science ®Google Scholar
• Ho, AD., Thaler, J., Stryckmans, P., et al. (1990) "Pentostatin in refractory chronic lymphocytic leukemia: a phase II trial of the European Organization for Research and Treatment of Cancer", Journal of the National Cancer Institute, 82(17), 1416–1420.
   PubMed Web of Science ®Google Scholar
• Johnson, S.A., Catovsky, D., Child, JA., Newland, AC., Milligan, D.W. and Janmohamed, R. (1998) "Phase I/II evaluation of pentostatin (2'-deoxycoformycin) in a five day schedule for the treatment of relapsed/refractory B-cell chronic lymphocytic leukae-mia", Investigative New Drugs, 16(2), 155–160.
   PubMed Web of Science ®Google Scholar
• Gandhi, V. and Plunkett, W. (2002) "Cellular and clinical pharmacology of fludarabine", Clinical Pharmacokinetics, 41(2), 93— 103.
   PubMed Web of Science ®Google Scholar
• Oken, M.M., Creech, R.H., Tormey, D.C., et al. (1982) "Toxicity and response criteria of the Eastern Cooperative Oncology Group", American Journal of Clinical Oncology, 5(6), 649–655.
   PubMed Web of Science ®Google Scholar
• Cheson, B.D., Bennett, J.M., Rai, KR., et al. (1988) "Guidelines for clinical protocols for chronic lymphocytic leukemia: recommen-dations of the National Cancer Institute-sponsored working group", American Journal of Hematology, 29(3), 152— 163.
   PubMed Web of Science ®Google Scholar
• Kaplan, E.L. and Meier R. (1958) "Nonparametric estimation from incomplete observation", Journal of American Statistical Associa-tion, 53, 457–481.
   Web of Science ®Google Scholar
• Hochster, H.S., Oken, M.M., Winter, J.N., et al. (2000) "Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: results and and long-term follow-up —a report from the Eastern Cooperative Oncology Group", Journal of Clinical Oncology, 18(5), 987–994.
   PubMed Web of Science ®Google Scholar
• Frewin, R., Turner, D., Tighe, M., Davies, S., Rule, S. and Johnson, S. (1999) "Combination therapy with fludarabine and cyclopho-sphamide as salvage treatment in lymphoproliferative disorders", British Journal of Haematology, 104(3), 612–613.
   PubMed Web of Science ®Google Scholar
• Hallek, M., Schmitt, B., Wilhelm, M., et al. (2001) "Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group", British Journal of Haematology, 114(2), 342–348.
   PubMed Web of Science ®Google Scholar
• O'Brien, S.M., Kantarjian, H.M., Cortes, J., et al. (2001) "Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia", Journal of Clinical Oncology, 19(5), 1414 — 1420.
   PubMed Web of Science ®Google Scholar
• Flinn, I.W., Byrd, J.C., Morrison, C., et al. (2000) "Fludarabine and cyclophosphamide with filgrastim support in patients with pre-viously untreated indolent lymphoid malignancies", Blood, 96(1), 71–75.
   PubMed Web of Science ®Google Scholar
• Kraut, E.H., Neff, J.C., Bouroncle, BA., Gochnour, D. and Greyer, M.R. (1990) "Immunosuppressive effects of pentostatin", Journal of Clinical Oncology, 8(5), 848–855.
   PubMed Web of Science ®Google Scholar
• Lazzarino, M., Orlandi, E., Baldanti, F., et al. (1999) "The immunosuppression and potential for EBV reactivation of fludar-abine combined with cyclophosphamide and dexamethasone in patients with lymphoproliferative disorders", British Journal of Haematology, 107(4), 877–882.
   PubMed Web of Science ®Google Scholar
• Vose, J.M., Cabanillas, F., O'Brien, S., Dang, N., Drapkin, R. and Foss, F. (2000) "Infectious complications of pentostatin therapy", Oncology (Huntingt), 14(6 Suppl 2), 41–42.
   PubMedGoogle Scholar
• Weiss, MA., Maslak, PG., Jurcic, J.G., et al. (2003) "Pentostatin and Cyclophosphamide: An Effective New Regimen in Previously Treated Patients with Chronic Lymphocytic Leukemia", Journal of Clinical Oncology, 21(7), 1278–1284.
   PubMed Web of Science ®Google Scholar